COMMUNIQUÉS West-GlobeNewswire
-
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
21/05/2026 -
PacBio to Participate in the Jefferies Global Healthcare Conference
21/05/2026 -
Lunavelle Sleep Patches Claims Evaluated: Most Effective Melatonin-Free Patches for Deeper Rest with Time-Tested Ingredients Proven To Work
21/05/2026 -
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
21/05/2026 -
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
21/05/2026 -
Legend Biotech Announces Presentations at ASCO 2026
21/05/2026 -
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
21/05/2026 -
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
21/05/2026 -
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
21/05/2026 -
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
21/05/2026 -
Paul Cobbo to head leading Brisbane NDIS provider Orange Plan Management
21/05/2026 -
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
21/05/2026 -
BulkGLP Announces Dual-Tier Quality Verification Protocol for Global Supply of Analytical Reference Materials
21/05/2026 -
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
21/05/2026 -
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026
21/05/2026 -
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
21/05/2026 -
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
21/05/2026 -
NMDP Gala in New York City Raises Record-Breaking $660,000 Enabling More Patients to Receive Life-Saving Cell Therapy
21/05/2026 -
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
21/05/2026
Pages